Published 29 December 2008, doi:10.1136/bmj.a2735
Cite this as: BMJ 2008;337:a2735

Editorials

Changes to the regulation of drug prices in the UK

Now the prices paid should reflect a medicine’s clinical value

The first 150 words of the full text of this article appear below.

On 11 December 2008 the Department of Health and the Association of the British Pharmaceutical Industry jointly published details of an agreement they had reached after nine months’ negotiation for the pricing of brand name drugs sold to the NHS.¹ The new terms, which came into effect on 1 January 2009 and will run for five years, are the latest in a continually evolving Pharmaceutical Price Regulation Scheme.

Under the framework of this scheme, which was originally known as the Voluntary Price Regulation Scheme, government and industry have been negotiating "voluntary and non-contractual" terms for drug pricing since 1956, and the previous set of terms—which started in 2005—was due to run until 2010. However, in 2007 a market report from the Office of Fair Trading argued that the scheme was outdated, perverse, and not fit for purpose, and demanded that it be reformed.² The government unilaterally withdrew from the 2005-10 . . . [Full text of this article]

¹ St George’s Medical School, London SW17 0RE

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Article

Doctors, patients, and the pharmaceutical industry

Joe Collier
BMJ 2009 338: b443. [Extract] [Full Text]

This article has been cited by other articles:

• Collier, J. (2009). Doctors, patients, and the pharmaceutical industry. BMJ 338: b443-b443 [Full text]  

Online poll

Find out more on doc2doc >>